Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Behavior, Psychology and Sociology

The role of Lifestyle Medicine in obesity management: a complementary approach

International Journal of Obesity volume 50, pages 6–7 (2026)Cite this article

Subjects

Lifestyle Medicine (LM) is a rapidly growing, evidence-based specialty emphasizing six pillars—nutrition, physical activity, restorative sleep, stress management, avoidance of risky substances, and positive social connections—to prevent, treat, and potentially reverse chronic diseases, including obesity [1]. While Obesity Medicine (OM) specialists routinely incorporate lifestyle interventions as the base of the therapeutic pyramid [2], many may not be familiar with LM as a distinct discipline. In fact, with the recent success of game-changing anti-obesity medications (AOMs) like semaglutide and tirzepatide, some may even question the relevance of lifestyle-based treatments for obesity [3]. This article outlines the role of LM specialists in obesity management and the potential of LM to enhance multidisciplinary care.

There is considerable overlap between the areas of focus of LM and OM specialists. Both disciplines facilitate modifications in dietary patterns and physical activity when treating obesity and other chronic illnesses. Both will counsel patients on getting a sufficient quantity and quality of sleep and screen for common comorbidities like obstructive sleep apnea. Given the challenges of behavior change, both specialties train providers in motivational interviewing and other behavior change techniques to support patients in making healthy lifestyle changes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lippman D, Stump M, Veazey E, Guimarães ST, Rosenfeld R, Kelly JH, et al. Foundations of Lifestyle Medicine and its evolution. Mayo Clin Proc Innov Qual Outcomes. 2024;8:97–111.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Tucker S, Bramante C, Conroy M, Fitch A, Gilden A, Wittleder S, et al. The most undertreated chronic disease: addressing obesity in primary care settings. Curr Obes Rep. 2021;10:396–408.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lewis KH, Moore JB, Ard JD. Game changers: do new medications make lifestyle-based treatment of obesity obsolete? Obesity. 2024;32:237–9.

    Article  CAS  PubMed  Google Scholar 

  4. Hauser ME, McMacken M, Lim A, Shetty P. Nutrition-an evidence-based, practical approach to chronic disease prevention and treatment. J Fam Pract. 2022;71:S5–s16.

    PubMed  Google Scholar 

  5. Kligler B. Whole Health in the Veterans Health Administration. Glob Adv Health Med. 2022;11:2164957x221077214.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LFV, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

    Article  CAS  PubMed  Google Scholar 

  7. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325:1403–13.

    Article  CAS  PubMed  Google Scholar 

  8. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16.

    Article  CAS  PubMed  Google Scholar 

  9. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29:2909–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wadden TA, Neiberg RH, Wing RR, Clark JM, Delahanty LM, Hill JO, et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity. 2011;19:1987–98.

    Article  PubMed  Google Scholar 

  11. Pantalone KM, Xiao H, Bena J, Morrison S, Downie S, Boyd AM, et al. Type 2 diabetes pharmacotherapy de-escalation through ai-enabled lifestyle modifications: a randomized clinical trial. NEJM Catalyst. 2025;6:CAT.25.0016.

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX, USA

    Bethany Agusala

  2. Sharp Rees-Stealy Medical Group, San Diego, CA, USA

    John Clark

Authors
  1. Bethany Agusala
    View author publications

    Search author on:PubMed Google Scholar

  2. John Clark
    View author publications

    Search author on:PubMed Google Scholar

Contributions

BA and JC both contributed to the concept and design of this manuscript. BA performed initial drafting. JC provided critical revisions. BA and JC both agreed on the final drafting and submission of this manuscript.

Corresponding author

Correspondence to Bethany Agusala.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agusala, B., Clark, J. The role of Lifestyle Medicine in obesity management: a complementary approach. Int J Obes 50, 6–7 (2026). https://doi.org/10.1038/s41366-025-01937-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41366-025-01937-9

Search

Advanced search

Quick links